Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Swallowing Outcomes and ctDNA in HPV+ Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
NCT04920344Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cisplatin micelle injection (HA132) in oropharyngeal cancer (3 arms), sponsored by Rutgers University. Primary endpoint: MD Anderson Dysphagia Index. Started May 2021; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT04920344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920344.